Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«TP53

Below is an extended TP53 research listing. Click here to return to the gene page.

Recent Publications on :

The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis.
In their paper in this issue of the Journal, Xian et al have analysed in...
Direct Link
3rd November, 2009
Bute Medical School, University of St Andrews and Department of Pathology,
Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect.
Due to patterns of migration, selection, and population expansion, founder...
Direct Link
31st October, 2009
International Agency for Research on Cancer (IARC), Lyon, Rhone, 69372,
Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.
Disruption or loss of tumor suppressor gene TP53 is implicated in the...
Direct Link
31st October, 2009
Departamento de Genetica, Laboratorio de Oncogenetica, Faculdade de
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. 30th October, 2009
Department of Hematopathology.
Benzene-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a functional assay, the functional analysis of separated alleles in yeast, in human lung cells.
Recent concern has centred on the effects of continuous exposure to low...
Direct Link
29th October, 2009
LCE EA2598, Toxicologie Industrielle et Environnementale, Universite du
Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients.
PURPOSE: Despite multimodal aggressive treatment glioblastoma patients...
Direct Link
29th October, 2009
Authors' Affiliations: Departments of Neuropathology and Neurosurgery,
High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Juvenile breast cancer is rare and poorly known. We studied a series of...
Direct Link
24th October, 2009
Unit of Molecular Pathology and Genomics, Aging Research Center (CeSI) G.
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage.
Deletion of TP53 gene, under routine assessment by FISH analysis, connects...
Direct Link
24th October, 2009
Department of Internal Medicine - Hematooncology, University Hospital Brno
Detection of chromosomal abnormalities associated with chronic lymphocytic leukemia: what is the best method?
B-cell chronic lymphocytic leukemia (CLL) follows a heterogeneous clinical...
Direct Link
20th October, 2009
Laboratory of Hematology and Cytogenetics, Hospital Avicenne, Bobigny
TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.
Genomic and immunologic surveillance mechanisms are crucial in protection...
Direct Link
20th October, 2009
Genomic Immunoepidemiology Laboratory, HUMIGEN LLC, Institute for Genetic
Arsenic exposure predicts bladder cancer survival in a US population.
PURPOSE: Chronic arsenic exposure at levels found in US drinking water has...
Direct Link
17th October, 2009
Section of Biostatistics and Epidemiology, Department of Community and
Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.
Tumor suppressor p53 plays a major role in colorectal cancer development....
Direct Link
15th October, 2009
Department of Medicine, Hem-Onc Section, University of Oklahoma Cancer
CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
PURPOSE: We evaluated DNA polymorphisms in genes related to DNA repair,...
Direct Link
14th October, 2009
Institute of Pathology, Technische Universitat Munchen, Trogerstr. 18,
Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.
BACKGROUND: The aim of the study was to assess the efficacy of pegylated...
Direct Link
13th October, 2009
Istituto Oncologico Veneto-IRCCS, Department of Pathology, University of
Molecular characterization of dedifferentiated mucoepidermoid carcinoma of the trachea using laser microdissection-based TP53 mutation analysis.
BACKGROUND: The aim of the study was to assess the efficacy of pegylated...
Direct Link
13th October, 2009

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.